SAGE-718 Emerging Drug Insight

“SAGE-718 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about SAGE-718 for Huntington’s disease in the 7MM. A detailed picture of the SAGE-718 for Huntington’s disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the SAGE-718 for Huntington’s disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAGE-718 market forecast, analysis for Huntington’s disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Huntington’s disease.

Drug Summary

SAGE-718 is a novel, oral, first-in-class, oxysterol-based positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors. SAGE-718 is the lead compound from Sage's NMDA modulator platform. It is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease.

NMDA receptors are glutamate-gated cation channels that play a critical role in the health and regulation of neurons, and are involved in learning, memory, and neuroplasticity. Positive modulation of NMDA receptors may have potential benefit in the treatment of conditions associated with NMDA hypofunction and disorders associated with a high prevalence of anti-NMDA antibodies, as well as in disorders associated with reductions in plasma cerebrosterol, such as Huntington's disease and Alzheimer's disease.

SAGE-718 is currently being studied in the ongoing Phase III (NCT05655520) and Phase II (NCT05107128; DIMENSION) clinical trials to evaluate the safety and tolerability of SAGE-718 and the effect of SAGE-718 on cognitive performance and functioning in participants with HD (Huntington's disease). The company has completed one Phase I (NCT03787758) double-blind, placebo-controlled, multiple ascending dose study to determine the safety, tolerability, and pharmacokinetics of SAGE-718 oral solution in healthy adults (Part A) with an open-label cohort of patients with HD (Part B).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the SAGE-718 description, mechanism of action, dosage and administration, research and development activities in Huntington’s disease.
• Elaborated details on SAGE-718 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SAGE-718 research and development activity in Huntington’s disease in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SAGE-718 (Deutetrabenazine).
• The report contains forecasted sales of SAGE-718 for Huntington’s disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Huntington’s disease.
• The report also features the SWOT analysis with analyst views for SAGE-718 in Huntington’s disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAGE-718 Analytical Perspective by DelveInsight

• In-depth SAGE-718 Market Assessment

This report provides a detailed market assessment of SAGE-718 in Huntington’s disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• SAGE-718 Clinical Assessment

The report provides the clinical trials information of SAGE-718 in Huntington’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Huntington’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAGE-718 dominance.
• Other emerging products for Huntington’s disease are expected to give tough market competition to SAGE-718 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAGE-718 in Huntington’s disease.
• Our in-depth analysis of the forecasted sales data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAGE-718 in Huntington’s disease.

Key Questions

• What is the product type, route of administration and mechanism of action of SAGE-718?
• What is the clinical trial status of the study related to SAGE-718 in Huntington’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAGE-718 development?
• What are the key designations that have been granted to SAGE-718 for Huntington’s disease?
• What is the forecasted market scenario of SAGE-718 for Huntington’s disease?
• What are the forecasted sales of SAGE-718 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Huntington’s disease and how are they giving competition to SAGE-718 for Huntington’s disease?
• Which are the late-stage emerging therapies under development for the treatment of Huntington’s disease?